Molbio Diagnostics Raises ₹281.5 Cr from Anchor Investors for IPO
By ThePip Desk
Molbio Diagnostics secures ₹281.5 crore from 33 anchor investors ahead of its ₹940 crore IPO, allotting shares at ₹807 each. Read more about the IPO details.
Molbio Diagnostics secured INR 281.5 crore from 33 anchor investors, setting the stage for its INR 940 crore Initial Public Offering (IPO). This pre-IPO funding involved allotting 34.88 lakh equity shares at INR 807 each, the upper end of its IPO price band.
IPO Overview
- Total IPO target: INR 940 crore
- Public subscription window: August 10 to August 12, 2026
- Fresh issue component: INR 200 crore
- Anchor investors involved: 33 entities
The total public issue combines the fresh equity with an offer for sale by existing shareholders. Molbio Diagnostics, backed by Temasek and Motilal Oswal Group, specializes in molecular diagnostics solutions.
Key Anchor Investor Participants
- Goldman Sachs
- BlackRock Global Funds
- Mirae Asset
- Nippon India Mutual Fund
- ICICI Prudential Mutual Fund
- Kotak Mutual Fund
- Tata Mutual Fund
- WhiteOak Capital
- Bajaj Life Insurance
- HDFC Life Insurance
The Goa-based company is recognized for its Truenat platform, a portable, real-time PCR-based molecular diagnostics system. This technology supports decentralized testing for various infectious and non-communicable diseases, particularly in settings with limited resources.
Use of Fresh Issue Proceeds
- Expand research and development infrastructure for an integrated R&D center in Bengaluru.
- Automate existing test-kit and device manufacturing facilities.
The capital raised through the fresh issue is specifically earmarked for these strategic investments. The IPO proceeds aim to boost Molbio Diagnostics’ manufacturing capabilities and innovation pipeline.